Exendin-4 Modulates Diabetes Onset in Nonobese Diabetic Mice
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Activation of the glucagon-like peptide-1 receptor (GLP-1R) is associated with expansion of β-cell mass due to stimulation of cell proliferation and induction of antiapoptotic pathways coupled to β-cell survival. Although the GLP-1R agonist Exenatide (exendin-4) is currently being evaluated in subjects with type 1 diabetes, there is little information available about the efficacy of GLP-1R activation for prevention of experimental type 1 diabetes. We examined the consequences of exendin-4 (Ex-4) administration (100 ng once daily and 2 μg twice daily) on diabetes onset in nonobese diabetic mice beginning at either 4 or 9 wk of age prior to the onset of diabetes. Ex-4 treatment for 26 wk (2 μg twice daily) initiated at 4 wk of age delayed the onset of diabetes (P = 0.007). Ex-4-treated mice also exhibited a significant reduction in insulitis scores, enhanced β-cell mass, and improved glucose tolerance. Although GLP-1R mRNA transcripts were detected in spleen, thymus, and lymph nodes from nonobese diabetic mice, Ex-4 treatment was not associated with significant changes in the numbers of CD4+ or CD8+ T cells or B cells in the spleen. However, Ex-4 treatment resulted in an increase in the number of CD4+ and CD8+ T cells in the lymph nodes and a reduction in the numbers of CD4+CD25+Foxp3+ regulatory T cells in the thymus but not in lymph nodes. These findings demonstrate that sustained GLP-1R activation in the absence of concomitant immune intervention may be associated with modest but significant delay in diabetes onset in a murine model of type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Studies to date that have reported an increase in β-cell mass with glucagon-like peptide 1 (GLP-1)-1 based therapies were undertaken in young rodents (17–21).”
From Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice (2009) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · cited 1×
“Total protein levels in extracts were determined using the Bradford method (19) with dye reagent (Bio-Rad Laboratories, Inc.”
MethodDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 16×
“The cytoprotective and regenerative properties of GLP-1R agonists have raised the possibility that prolonged treatment of patients with T2DM using GLP-1R agonists such as exendin-4 (Exenatide) might be associated with preservation or enhancement of -cell mass, parameters that remain difficult to assess in human subjec…”
BackgroundResultInfluentialSelf-citationRegulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3
Fontenot, J. D., Rasmussen, J. P., Williams, L. M., Dooley, J. L., Farr, A. G., & Rudensky, A. Y. (2005) · Immunity · doi:10.1016/j.immuni.2005.01.016 · Cited by 2,279
International trial of the Edmonton protocol for islet transplantation
Shapiro, A. M. J., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Brendel, M. D., Berney, T., Brennan, D. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061267 · Cited by 1,942
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Self-citationStoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Self-citationGlucagon-like peptide-1 prevents beta cell glucolipotoxicity
Joly, E., Prentki, M., Buteau, J., El-Assaad, W., Rhodes, C. J., & Rosenberg, L. (2004) · Diabetologia · doi:10.1007/s00125-004-1379-6 · Cited by 337
Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice
Wang, Q., & Brubaker, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0828-3 · Cited by 312 · cited 1×
“GLP-1R agonists reduce -cell apoptosis in young db/db mice or in wild-type mice after administration of streptozotocin (8, 9).”
BackgroundDrucker, D. J. (2003) · Endocrinology · doi:10.1210/en.2003-1147 · Cited by 274
Self-citation
Research works printed but not linked: 1
- Masur K, Beinborn M, Zaenker KS 2004 Glucagon-like peptide-1 (GLP-1) is not only an important incretin hormone but also a modulator of the cellular immune system. Diabetes 53:A49-LB [Google Scholar]
Cited by
Items 101–108 of 108
Lee, M., & Kim, K. (2009) · Journal of Korean Medical Association · doi:10.5124/jkma.2009.52.7.677
Sanjeevi, C. B., & Sun, C. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_19
Pérez-Arana, G.-M., Blandino-Rosano, M., Oliveira, J. A. P., & Aguilar‐Diosdado, M. (2010)
Lim, G. E. (2010) · TSpace (University of Toronto) · Cited by 1
EFFECTS OF EXENDIN-4 AND ANTIOXIDANTS ON ADULT DIABETIC MALE ALBINO RATS
Shawer, G. A., Ahmed, Y. E.-A., Fahmi, M. A.-A., El-Aziz, M. A. E.-A. A., & Elsalamoni, M. A. (2016) · Al-Azhar Medical Journal · doi:10.12816/0029126
“Exendin-4 or incretin mimetic has structural similarity and binds to GLP1receptors (Hadjiyanni et al., 2008).”
BackgroundZarogiannis, S. (2019) · doi:10.47690/gdoaj.2019.1104
“Mice taking rAd-βGLP-1 had significantly increased insulin-positive cells in the pancreatic islets and C-peptide levels and the remission phase was 1 year longer compared to the control group [20].”
BackgroundSanjeevi, C. B., & Sun, C. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_19-2
Shi, Y., Yang, X., Luo, X., Yang, J., Zhang, Y., Chen, G., & Hou, L. (2026) · Cells · doi:10.3390/cells15131203
“Basic studies have reported that GLP-1 receptor agonists can reduce the level of pancreatic islet inflammation, improve glucose tolerance, and delay the onset of diabetes in NOD mice [32,33].”
Metadata
- Authors
- Hadjiyanni, I., Baggio, L. L., Poussier, P., & Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Drucker, Daniel J.
- ORCID
- Drucker, Daniel J.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2007-12-06
- Volume
- 149
- Issue
- 3
- Pages
- 1338-1349
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- PMC
- PMC2275367
- OpenAlex
- W2172277730
- Cited by
- 110
- References
- 34
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 5 · 2023: 1 · 2022: 7 · 2021: 3 · 2020: 2 · 2019: 9 · 2018: 3 · 2017: 2 · 2016: 5 · 2015: 2 · 2014: 9 · 2013: 11 · 2012: 10
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrinology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- exendin-4, GLP-1 receptor, type 1 diabetes prevention, NOD mice, insulitis, beta-cell mass, glucose tolerance, regulatory T cells, CD4+ T cells, CD8+ T cells, diabetes onset
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Diabetes Mellitus, Experimental, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Hypoglycemic Agents, Lymph Nodes, Peptides, Spleen, Venoms, CD4-Positive T-Lymphocytes, Mice, Inbred NOD, Receptors, Glucagon, CD8-Positive T-Lymphocytes, Disease Progression, Insulin-Secreting Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.